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Abstract
During chronic kidney disease (CKD), there is a progressive accumulation of toxic solutes due to inadequate renal clearance.
Here, the interaction between uremic toxins and two important efflux pumps, viz. multidrug resistance protein 4 (MRP4) and
breast cancer resistance protein (BCRP) was investigated. Membrane vesicles isolated from MRP4- or BCRP-overexpressing
human embryonic kidney cells were used to study the impact of uremic toxins on substrate specific uptake. Furthermore,
the concentrations of various uremic toxins were determined in plasma of CKD patients using high performance liquid
chromatography and liquid chromatography/tandem mass spectrometry. Our results show that hippuric acid, indoxyl
sulfate and kynurenic acid inhibit MRP4-mediated [3H]-methotrexate ([3H]-MTX) uptake (calculated Ki values: 2.5 mM, 1 mM,
25 mM, respectively) and BCRP-mediated [3H]-estrone sulfate ([3H]-E1S) uptake (Ki values: 4 mM, 500 mM and 50 mM,
respectively), whereas indole-3-acetic acid and phenylacetic acid reduce [3H]-MTX uptake by MRP4 only (Ki value: 2 mM and
IC50 value: 7 mM, respectively). In contrast, p-cresol, p-toluenesulfonic acid, putrescine, oxalate and quinolinic acid did not
alter transport mediated by MRP4 or BCRP. In addition, our results show that hippuric acid, indole-3-acetic acid, indoxyl
sulfate, kynurenic acid and phenylacetic acid accumulate in plasma of end-stage CKD patients with mean concentrations of
160 mM, 4 mM, 129 mM, 1 mM and 18 mM, respectively. Moreover, calculated Ki values are below the maximal plasma
concentrations of the tested toxins. In conclusion, this study shows that several uremic toxins inhibit active transport by
MRP4 and BCRP at clinically relevant concentrations.
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Introduction
Approximately 5% of the adult population in the developed
countries suffers from chronic kidney disease (CKD) stage III-V,
which is defined by a decreased estimated glomerular filtration
rate (eGFR) [1]. A main feature at this stage of CKD is the
accumulation of solutes that are normally excreted in urine. These
uremic retention solutes, also known as uremic toxins, are a
heterogeneous group of organic compounds. Currently, 110
compounds are considered to be uremic toxins and they are
classified into three groups depending on their chemical properties
that largely influence the possibility to remove these toxins using
current dialysis strategies, namely size and solubility. The currently
defined groups, as described by Vanholder et al. 2008, are: (1) the
small water-soluble compounds, with a molecular weight (MW)
arbitrarily set at #500 Da, for example, urea and creatinine; these
compounds are easily removed via dialysis and their toxic potential
is limited. (2) The middle molecules, with a MW.500 Da, such as
b2-microglobulin; due to their size, these retention solutes can only
be cleared using dialyzer membranes with large pores, which focus
on filtration via convection instead of diffusion. (3) The protein-
bound solutes; the compounds in this group mostly have a small
MW and prototypes include indoxyl sulfate and p-cresol sulfate.
Solutes belonging to this group are very difficult to clear using
current dialysis strategies and they exhibit toxic effects [2]. Uremic
toxins are thought to contribute to the plethora of pathologies
observed in patients with CKD, including anemia, bone disorders,
renal fibrosis and cardio-vascular disease. Administration of the
oral sorbent AST-120 is currently the only therapy to prevent
accumulation of protein-bound uremic toxins in patients with
CKD. Unfortunately, AST-120 prevents no more than the uptake
of indoxyl sulfate and p-cresol in the intestinal tract [3].
Understanding the endogenous clearance of protein-bound solutes
could lead to the development of novel therapeutic strategies for
the removal of uremic toxins.
In the healthy population, uremic toxins are cleared by the
kidney and this process is largely dependent on glomerular
filtration and tubular secretion via a multitude of transport
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proteins expressed in renal proximal tubules. Moreover, it has
been demonstrated that both organic anion transporter (OAT) 1
and OAT3 play important roles in the renal tubular uptake of
uremic toxins and organic anions [4–6]. Both transporters show
overlapping substrate specificities, but differential contributions to
uremic toxin clearance have been reported as well. For example,
indoxyl sulfate is equally transported by OAT1 and OAT3, but
indole-3-acetic acid and hippuric acid are preferable substrates for
OAT1, and uptake of 3-carboxy-4-methyl-5-propyl-2-furanpro-
pionate is mediated by OAT3 solely [6]. In addition, using a rat
model of renal failure, the basolaterally expressed kidney-specific
organic anion transporting polypeptide 4C1 (SLCO4C1) was
recently shown to facilitate the removal of several uremic toxins,
including guanidino succinate, in the proximal tubule [7]. Thus,
basolateral uptake of uremic toxins in renal proximal tubules cells
is fairly well characterized, however, little is known about the
transport of uremic toxins over the apical membrane into urine.
Two important renal efflux pumps at the apical membrane are
multidrug resistance protein 4 (MRP4) and breast cancer
resistance protein (BCRP) [8,9]. Both MRP4 and BCRP are
known to transport urate, [10,11] a uremic toxin involved in the
pathogenesis of gout and cardiovascular disease [12]. Further-
more, functional and nonfunctional mutations in the BCRP gene
cause hyperuricemia-based gout, supporting the importance of the
efflux pump in urate secretion [11,13]. Therefore, it seems likely
that both MRP4 and BCRP are involved in the transport of
uremic toxins into the proximal tubule lumen.
The present study was designed to investigate the interaction
between several uremic toxins, mainly belonging to the group of
protein-bound solutes, and MRP4- and BCRP-mediated trans-
port. Our results show that hippuric acid, indoxyl sulfate and
kynurenic acid inhibit substrate specific uptake by both MRP4 and
BCRP, whereas indole-3-acetic acid and phenylacetic acid only
reduce transport by MRP4. Moreover, inhibition of transport by
multiple uremic toxins mainly occurs at clinically relevant
concentrations, suggesting that uremic toxins may contribute to
the many complications of CKD.
Materials and Methods
Ethics Statement
The ethical committee of the Radboud University Nijmegen
Medical Centre on research involving human subjects approved
this study, and oral informed consent was obtained from each
patient and each healthy volunteer.
Chemicals
All chemicals were obtained from Sigma (Zwijndrecht, the
Netherlands) unless stated otherwise. Stock solutions of uremic
toxins were prepared as previously described [14], and stored at
220 uC. [39,59,79-3H(n)]-methotrexate disodium salt ([3H]-MTX)
with a specific activity ranging between 13.4 and 25.3 Ci/mmol
was purchased from Moravek (Brea, USA) and [69,79-3H(n)]-
estrone-sulfate ammonium salt ([3H]-E1S) with a specific activity
of 54.26 Ci/mmol was obtained from Perkin Elmer (Groningen,
the Netherlands).
Cell culture and transfection
Human embryonic kidney (HEK293; purchased at American
Type Culture Collection, Manassas, VA) cells were cultured in
Dulbecco’s modified Eagle’s medium (Invitrogen life sciences,
Breda, the Netherlands) containing 10% (v/v) fetal calf serum (MP
Biomedicals, Uden, the Netherlands) at 37uC in a 5% (v/v) CO2
atmosphere. To functionally overexpress MRP4 and BCRP,
HEK293 cells were transduced with baculoviruses of human
MRP4, BCRP or enhanced yellow fluorescent protein (EYFP),
generated via the Bac-to-Bac system (Invitrogen) as previously
described [15]. To transduce HEK293 cells, they were cultured in
500 cm2 flasks until 70% confluence. Subsequently, medium was
removed and 10 ml of virus and 25 ml of medium were added and
incubated for 30 min at 37uC. Next, 50 ml of medium was added
and after 2 h of transduction 5 mM sodium butyrate was added.
Membrane vesicle preparation
Three days after transduction, cells were harvested and pelleted
by centrifugation (30 min at 4,000 x g). Afterwards, the cells were
resuspended in ice-cold hypotonic TS buffer (0.5 mM sodium
phosphate, 0.1 mM EDTA, pH 7.0) containing protease inhibi-
tors (100 mM phenylmethylsulfonyl fluoride, 5 mg/ml aprotinin,
5 mg/ml leupeptin, 1 mg/ml pepstatin and 1 mg/ml E-64) and
shaken for 30 min at 4uC. Cells were then centrifuged at
100,000 x g for 30 min at 4uC. Subsequently, pellet was
resuspended in ice-cold isotonic buffer (10 mM Tris-HEPES and
250 mM sucrose, pH 7.4, adjusted with HEPES) supplemented
with protease inhibitors and homogenized using a tight fitting
Dounce homogenizer followed by centrifugation (1,000 x g,
20 min, 4uC). Afterwards, supernatant was centrifuged at
100,000 x g for 1 h at 4uC. The resulting pellet was resuspended
in isotonic buffer and passed through a 27-gauge needle 25 times
to obtain crude membrane vesicles. The protein content of
samples was determined using the Bio-Rad protein assay
(Veenendaal, the Netherlands), according to manufacturers
recommendations. Vesicles were frozen in liquid nitrogen and
stored at 280uC until use. The orientation of the membrane
vesicles was not determined, since ATP-dependent uptake occurs
only in inside-out vesicles.
Western blotting
Overexpression of MRP4 or BCRP in membrane vesicles was
studied using the Odyssey western blotting technique. Total
protein (15 mg) was separated via SDS/PAGE using a 10% (w/v)
gel, and blotted onto nitrocellulose membranes using the iBlot dry
blotting system (Invitrogen). Afterwards, the membrane was
blocked using Odyssey Blocking Buffer, (1:1 diluted with PBS;
Westburg BV, Leusden, the Netherlands) for 1 hour at RT. The
membrane was then incubated overnight at 4uC with rabbit-a-
MRP4 (1:5,000; van Aubel et al. [8]) or mouse-a-BCRP (1:200;
Clone BXP-21; Kamiya Biomedical, Seattle, USA) in Odyssey
Blocking Buffer containing 0.1% (v/v) Tween-20. Afterwards, the
membrane was thoroughly washed three times during 10 min with
PBS containing 0.1% (v/v) Tween-20. The secondary antibodies,
goat-a-rabbit IRDye 800 (1:10,000; Sigma) and goat-a-mouse
Alexa Fluor 680 (1:10,000; Rockland, Heerhugowaard, the
Netherlands), were incubated for 1 hour at RT in Odyssey
Blocking Buffer containing 0.1% (v/v) Tween-20 and 0.01% (w/v)
SDS. The membrane was thoroughly washed, as described above,
and then scanned using the Odyssey Infrared Imaging System (LI-
COR Biotechnology). Expression of MRP4 was assessed using
channel 800 and BCRP expression was determined using channel
700.
Membrane vesicle transport inhibition assay
A rapid filtration technique was used to study the uptake of
[3H]-MTX and [3H]-E1S into MRP4 or BCRP membrane
vesicles, as previously described [16]. In short, 25 ml of TS buffer
containing 4 mM ATP, 10 mM MgCl2 and radiolabeled substrate
was added to 5 ml of the membrane vesicles (1.5 mg/ml). The
transport assay was performed in the absence or presence of
Uremic Toxin-Induced Transport Inhibition
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various concentrations of uremic toxins to evaluate the inhibitory
effects of these compounds on MRP4-mediated [3H]-MTX uptake
and BCRP-mediated [3H]-E1S uptake. Transport was started by
incubating the mixture at 37uC for 1 min (BCRP) or 10 min
(MRP4), time points at which substrate uptake was previously
shown to be linear [15,17]. Uptake was stopped by placing the
samples on ice and the addition of 150 ml ice cold TS buffer.
Subsequently, the samples were transferred to a 96 well filter plate
(Millipore, Etten-leur, the Netherlands) pre-incubated with TS
buffer and filtered using a Multiscreen HTS-Vacuum Manifold
filtration device (Millipore). Afterwards, 2 ml of scintillation liquid
was added to each filter and radioactivity was determined using
liquid scintillation counting. As negative controls ATP was
substituted for AMP and EYFP-membrane vesicles were used.
Each experiment was performed in triplicates.
High-performance liquid chromatography (HPLC)
Blood samples were obtained from 4 patients with chronic renal
failure (CRF) during regular check-up, 6 patients with end-stage
renal disease (ESRD) before hemodialysis and 4 healthy controls.
Clinical characteristics of study subjects are listed in Table 1. None
of the subjects had been fasting at the time of blood sampling.
Blood was collected in an EDTA Vacutainer and was immediately
centrifuged at 3,000 x g for 10 min. Subsequently, plasma was
collected and stored at 220uC. Before chromatography an aliquot
of plasma was diluted in H2O (1:1) and deproteinized with
perchloric acid (final concentration 3.3% (v/v)). Next, samples
were centrifuged at 12,000 x g for 3 min and 50 ml of the
supernatant was injected into the HPLC-system (Spectra-Physics
Analytical, Spectrasystem SCM400). To measure indole-3-acetic
acid, indoxyl sulfate and hippuric acid, the HPLC was equipped
with a C18 HPLC column (GraceSmart RP 18 5 u 15064.6 mm;
Grace, Breda, the Netherlands). Separation was performed at a
flow rate of 1 ml/min with eluent A (95% (v/v) H2O, 5% (v/v)
acetonitril and 0.1% (v/v) heptafluorobutyric acid) and eluent B
(50% (v/v) H2O, 50% (v/v) acetonitrile and 0.1% (v/v)
heptafluorobutyric acid) under the following gradient conditions:
0–1 min, 100% eluent A; 1–15 min, 100–25% eluent A; 15–
17 min, 25% eluent A; 17–18 min, 0–100% eluent A; 18–23 min,
100% eluent A. The compounds were detected at a wavelength of
230 nm. For the detection of phenylacetic acid, chromatography
was performed on a C18 HPLC column (Polaris 3 C18-A
15064.6 mm; Varian, Middelburg, the Netherlands) with eluent
A (97% (v/v) 50 mM sodium phosphate buffer [pH 6.5] and 3%
(v/v) methanol) and eluent B (50% (v/v) H2O, 49% (v/v)
acetonitrile and 1% (v/v) tetrahydrofuran) using the following
gradient: 0–1 min, 100% eluent A; 1–15 min, 100–90% eluent A;
15–18 min, 10–100% eluent B; 18–22 min, 100% eluent B; 22–
25 min, 0–100% eluent A; 25–30 min, 100% eluent A. The flow
rate was 1 ml/min and phenylacetic acid was measured at a
wavelength of 215 nm. Standards of the compounds were also run
in order to quantify the amount of toxins found in the samples.
Acquired data were processed with PC1000 software (Spectrasys-
tem).
Liquid chromatography/tandem mass spectrometry (LC/
MS-MS)
To determine the levels of kynurenic acid, blood was collected
from CRF patients and processed as described above. Subse-
quently, 10 ml of the clear supernatant was injected into the LC/
MS-MS system that consisted of an Accela HPLC system (Thermo
scientific, Breda, the Netherlands) equipped with a C18 HPLC
column (VisionHT C18 B 10062 mm, 1.5 mm; Grace). Separa-
tion was performed at a flow rate of 150 ml/min with eluent A
(5 mM ammonium formate+0.01% (v/v) trifluoroacetic acid) and
eluent B (50% acetonitrile) under the following gradient
conditions: 0–10 min, 98–50% eluent A; 10–15 min, 50% eluent
A; 15–16 min, 50–98% eluent A; 16–21 min, 98% eluent A. The
fractions eluted were directly passed through a TSQ Vantage
tandem mass spectrometer (Thermo scientific) equipped with an
electro-spray ionization source operating in the positive ion mode.
The ion spray voltage was 4 kV, source temperature was 350uC
and collision gas pressure was 1.5 bar. Kynurinic acid and the
internal standard 1-methyl-tryptophan were quantified by selected
reaction monitoring (SRM). The following SRM transitions were
used: m/z 190 (parent ion) to m/z 89 and 144 (both product ions)
for kynurenic acid and m/z 219.1 (parent ion) to m/z 160 and
202.1 (product ions) for methyl-tryptophan. A calibration curve of
kynurenic acid was made to quantify the amount of toxin found in
the samples and the results were corrected using the internal
standard. Acquired data were processed with Thermo Xcaliber
software (Thermo scientific).
Kinetic analysis and statistics
Statistics were performed using GraphPad Prism 5.02 via an
unpaired t test or a Kruskal-Wallis test followed by a Dunn’s
Multiple Comparison test. Differences between groups were
considered to be statistically significant when p,0.05. The
software was also used to perform (non-)linear regression analysis,
curve fitting details are summarized in Table S1 . The mean IC50
and IC20 values were calculated from the inhibition curves used
for the Dixon analysis and to determine the inhibition constant
(Ki) from the Dixon plots. Transport inhibition studies were
performed in triplicate and repeated at least three times.
Results
Selection of uremic toxins
The number of solutes that are considered to be uremic toxins is
constantly increasing [18]. As stated before, protein-bound toxins
are difficult to eliminate via dialysis and, therefore, these toxins
accumulate and become players in the multitude of pathologies
observed in uremic patients. In our study, ten toxins were selected
containing one water-soluble solute (oxalate) and nine protein-
bound solutes. The latter group contained four indoles (indoxyl
sulfate, indole-3-acetic acid, kynurenic acid and quinolinic acid),
three phenols (phenylacetic acid, p-cresol and p-toluenesulfonic
acid as a model compound for p-cresol sulfate), one hippurate
(hippuric acid) and one polyamine (putrescine). Chemical
characteristics of the solutes studied are depicted in Figure 1.
Table 1. Characteristics of study subjects.
CRF ESRD Control
Number 4 6 4
Age (years) 54620 58613 34610
Women (%) 25 33 25
Ureum (mmol/l) 3266 2166 ND
Creatinine (mmol/l) 5106210 720690 ND
Dialysis strategy NA 4 HD, 2 CAPD NA
Values are shown as mean 6 SD. CRF, chronic renal failure; ESRD, end-stage
renal disease; ND, not determined; NA, not applicable; HD, hemodialysis; CAPD,
continuous ambulatory peritoneal dialysis.
doi:10.1371/journal.pone.0018438.t001
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Expression of MRP4 and BCRP, and uptake of [3H]-MTX
and [3H]-E1S by membrane vesicles
Human embryonic kidney (HEK293) cells were transduced
using a baculovirus system to overexpress human MRP4, BCRP
or enhanced yellow fluorescent protein (EYFP; negative control).
Using the Odyssey Western blot technique, MRP4 and BCRP
were detected in membrane vesicles isolated from MRP4- and
BCRP-overexpressing HEK293 cells at 150 kD and 75 kD,
respectively. Protein expression of the transporters was absent in
EYFP-transduced cells, indicating that endogenous expression was
undetectable. For functionality of MRP4, the uptake of metho-
trexate (MTX) was investigated by using a radiotracer of the drug
[16]. Figure 2A shows that the ATP-dependent uptake of [3H]-
MTX in MRP4-overexpressing vesicles is 11-fold higher as
compared to EYFP vesicles with an average rate of 1.3 pmol/
mg*min. To determine the transport activity of BCRP, radioac-
tively labeled estrone sulfate (E1S) was used as typical substrate
[17]. BCRP-overexpressing vesicles showed 24-fold higher ATP-
dependent uptake of [3H]-E1S, compared to EYFP controls with
an average rate of 15.5 pmol/mg*min (Figure 2B). Furthermore,
Figure 2 demonstrates that for both transporters non-specific,
AMP-dependent, uptake is very low. Therefore, AMP-corrected
uptake is shown in subsequent figures. These results support the
functional expression of the transporters.
Uremic toxins inhibit transport
Using membrane vesicles overexpressing either transport
protein, the interaction between ten uremic toxins and substrate
specific transport by MRP4 and BCRP was studied. Hippuric acid
dose-dependently inhibited MRP4-mediated [3H]-MTX uptake
(Figure 3) and BCRP-mediated [3H]-E1S uptake (Figure 4) in a
concentration range of 0.1 mM to 3.5 mM. The compound did
not completely inhibit transport by MRP4, as depicted by the
plateau at 50% of the inhibition curve, whereas uptake of [3H]-
E1S by BCRP was completely blocked by hippuric acid. Indoxyl
sulfate inhibited transport by both MRP4 and BCRP at
concentrations ranging from 0.1 mM to 4 mM and 50 mM to
3 mM, respectively. Kynurenic acid inhibited substrate specific
uptake by both MRP4 and BCRP in a concentration range of
0.1 mM to 1 mM. In addition, our results illustrate that indole-3-
acetic acid and phenylacetic acid only reduced [3H]-MTX uptake
by MRP4 both at concentrations ranging from 0.1 mM to 5 mM.
Differences in initial substrate uptake arose from batch-to-batch
variations of the membrane vesicles, however, all vesicles used
demonstrated high substrate-specific uptake. The other toxins
tested, viz. oxalate, p-cresol, p-toluenesulfonic acid, putrescine and
quinolinic acid, did not decrease transport mediated by MRP4 or
BCRP with more than 10% at a concentration of 1 mM,
compared to control (Figure S1).
To investigate the mode of interaction, the uptake of three
different concentrations of substrate in the absence and presence
of uremic toxin was studied. The resulting inhibition curves were
transformed to a Dixon plot and analyzed by linear regression. As
depicted in the Dixon plots, most curves intersect with the x-axis,
indicating non-competitive inhibition. Figures 5 and 6 show that
hippuric acid and indoxyl sulfate inhibited MRP4-mediated
transport in a non-competitive manner, with a Ki of 25 mM and
1 mM, respectively. Both toxins also inhibited transport by BCRP
in a non-competitive fashion with a Ki of 4 mM and 0.5 mM,
respectively. Furthermore, our results indicated non-competitive
inhibition of MRP4-mediated transport by indole-3-acetic acid
(Ki: 2 mM) and kynurenic acid (Ki: 25 mM), while the latter
compound acted as a mixed inhibitor for [3H]-E1S transport by
BCRP. Mixed inhibition is considered to be composed of
competitive and non-competitive inhibition. The mode of
Figure 1. Selected uremic toxins. p-toluensulfonic acid was used as a model compound for p-cresol sulfate.
doi:10.1371/journal.pone.0018438.g001
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inhibition induced by phenylacetic acid, could not be elucidated
due to incomplete inhibition of MRP4-mediated transport by this
toxin. The kinetic analysis is summarized in Table 2.
Accumulation of uremic toxins in plasma
To investigate whether the observed transport inhibition induced
by several uremic toxins occurs at clinically relevant concentrations,
the plasma levels of these toxins were measured in CRF and ESRD
patients using HPLC and LC/MS-MS. Figure 7 illustrates that
mean hippuric acid levels increased from 2.2 mM to 25 mM in CRF
patients and to 160 mM in patients with ESRD. Furthermore, it was
observed that indoxyl sulfate concentrations markedly increased
from 13 mM (control) to 65 mM (CRF) and 129 mM (ESRD). The
levels of indole-3-acetic acid significantly increased in patients with
renal failure compared to control (2 mM), however, no differences
were observed between patients with CRF (4 mM) or ESRD (4 mM).
Furthermore, mean kynurenic acid levels significantly increased
from 0.05 mM to 0.6 mM in CRF patients and to 1 mM in patients
with ESRD. The mean plasma concentrations of phenylacetic acid
slightly increased during CKD (CRF: 4 mM, ESRD: 18 mM),
compared to control levels (5 mM), although not significantly.
Hence, the interindividual variability increased with disease
severity, with maximum concentrations reaching 9 mM in CRF
patients and 83 mM in patients with ESRD.
Inhibition of MRP4- and BCRP-mediated transport occurs
at clinical relevant concentrations
The calculated Ki and IC20 values were compared with the mean
plasma concentrations measured in ESRD patients during this
study (Cm), the highest mean/median (Cu) and the highest maximal
plasma concentrations (Cmax) measured in the literature in patients
with CKD are also shown. The IC20 value was used since we believe
that a 20% decrease in transport can already have a clinical impact.
The Cu and Cmax values were obtained from the online database of
the European Uremic Toxin (EUTox) Work Group (www.uremic-
toxins.org; [19]), unless stated otherwise. The results are summa-
rized in Table 2. Kynurenic acid potently inhibited transport by
MRP4, the Ki (25 mM) being notably lower than Cmax (50 mM) and
the IC20 (1.5 mM) similar to the mean concentration of this
compound. Furthermore, our results indicated that 50% of MRP4-
mediated uptake was inhibited by 2.5 mM hippuric acid, which is
lower than the Cmax of this solute (2.6 mM) and the IC20 (0.35 mM)
is four times lower than the Cu. Phenylacetic acid inhibited 50% of
the transport by MRP4 at a concentration lower than the Cmax
(7 mM vs. 7.7 mM), whereas, 20% of the transport was inhibited at
a concentration lower than the highest median plasma concentra-
tion (1.6 mM vs. 3.5 mM). Moreover, the Ki of indoxyl sulfate is
almost similar to the Cmax of this solute (1 mM vs. 940 mM),
whereas, the IC20 (530 mM) is approximately two-times below the
maximal concentration. Indole-3-acetic acid is the least potent
inhibitor of MRP4-mediated transport, with both the Ki (2 mM)
and the IC20 (570 mM) noticeably higher than the Cmax (52 mM).
BCRP-mediated transport is significantly inhibited by kynurenic
acid, with the Ki (50 mM) comparable to the peak uremic toxin
concentration (50 mM) and the IC20 (10 mM) lower than the Cmax.
Indoxyl sulfate acid inhibited 50% of the uptake by BCRP at a
concentration below the maximal uremic concentration (500 mM
vs. 940 mM). Furthermore, hippuric acid inhibited 20% of the [3H]-
E1S uptake by BCRP at a concentration almost two-fold lower than
the highest median uremic concentration (690 mM vs. 1.4 mM),
whereas the Ki (4 mM) was higher than the Cmax (2.6 mM).
Discussion
This study reports, for the first time, that several uremic toxins
directly inhibit transport by two important efflux pumps, viz.
Figure 2. Transport expression and activity in isolated membrane vesicles. HEK293 cells were transfected with a baculovirus of either
human MRP4 or BCRP. Cells transfected with EYFP were used as a negative control. Subsequently, membranes were isolated and vesicles were
prepared. Proteins were separated via SDS/PAGE and blotted onto nitrocellulose membranes. Blots were incubated with an antibody against MRP4 or
BCRP and the appropriated fluorescently labeled secondary antibodies. MRP4 was detected at 150 kD (upper panel A) and BCRP was detected at
75 kD (upper panel B). A rapid filtration technique was used to study the ATP-dependent uptake of [3H]-MTX into MRP4- overexpressing
membrane vesicles (lower panel A) and [3H]-E1S into BCRP membrane vesicles (lower panel B). As negative control ATP was substituted for AMP.
Results are presented as mean 6 SEM of one representative experiment performed in triplicate. M = marker, * = p,0.0001 compared to EYFP.
Experiments were performed at least three times.
doi:10.1371/journal.pone.0018438.g002
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MRP4 and BCRP, at clinically relevant concentrations. Since
MRP4 and BCRP are located at the apical membrane of proximal
tubule cells, transport activity depends on the intracellular levels of
substrates rather than substrate concentrations in the blood.
Previously, Masereeuw et al. demonstrated that methyl hippuric
acids accumulate during secretory transport in the isolated
perfused rat kidney [20,21]. Furthermore, they showed that 2-
methyl hippuric acid levels were 175-times higher in kidney tissue
compared to the perfusate and 4-methyl hippuric acid concentra-
tions were even 600-times higher. Thus, it is likely that
intracellular uremic toxin concentrations are much higher than
total plasma concentrations. This indicates that our results
probably underestimate the potential inhibitory effect of uremic
toxins on MRP4- and BCRP-mediated transport in vivo.
Both MRP4 and BCRP belong to the superfamily of ATP-
binding cassette (ABC) transporters, a family of transmembrane
proteins involved in the efflux of endo- and xenobiotics [22]. They
are expressed in several tissues including liver, intestine, brain and
the kidney [22,23]. In addition to their contribution to the renal
secretion of endogenous compounds, MRP4 and BCRP are
involved in the extrusion of a broad range of drugs [22]. Despite
their importance, little is known about the expression and activity
of both MRP4 and BCRP during renal disease. Lu et al. showed, in
a rat model of CKD, that BCRP gene expression decreased in
correlation with disease severity in male rats. In contrast, both
gene and protein expression of MRP4 remained unaltered [24].
Furthermore, it was demonstrated that following acute kidney
injury in mice the gene expression of MRP4 increased whereas the
expression of BCRP decreased. Conversely, protein expression of
both transporters showed an opposite effect [25]. The impact of
kidney disease on transporter expression and the inhibition of
transport activity by uremic toxins, as described in this study,
indicates that during CKD drug disposition may be altered leading
to an increased risk of adverse drug reactions.
Other transporters of the ABC family are P-glycoprotein (P-gp)
and MRP2. These transporters are also expressed in the apical
membrane of proximal tubule cells, amongst other tissues, and,
similar to MRP4 and BCRP, they are involved in the urinary
Figure 3. Uremic toxins inhibit MRP4-mediated transport. A rapid filtration technique was used to study uptake of [3H]-MTX into MRP4
membrane vesicles in the presence of various concentrations of uremic toxins. Radioactivity was determined using liquid scintillation counting.
Nonlinear regression analysis was performed using Graphpad Prism 5.02. Results are presented as mean 6 SEM of one representative experiment
performed in triplicate. Experiments were performed at least three times.
doi:10.1371/journal.pone.0018438.g003
Figure 4. Uremic toxins inhibit BCRP-mediated transport. A rapid filtration technique was used to study uptake of [3H]-E1S into BCRP
membrane vesicles in the presence of various concentrations of uremic toxins. Radioactivity was determined using liquid scintillation counting.
Nonlinear regression analysis was performed using Graphpad Prism 5.02. Results are presented as mean 6 SEM of one representative experiment
performed in triplicate. Experiments were performed at least three times.
doi:10.1371/journal.pone.0018438.g004
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excretion of drugs [22]. It was described that the activity of P-gp in
rat kidneys decreased following glycerol-induced acute kidney
injury, whereas, P-gp expression increased [26]. In addition, it was
demonstrated in rats that CRF induced the expression of MRP2 in
the kidney while P-gp expression remained unaltered [27].
Although P-gp and MRP2 have not been associated with uremic
toxin clearance, these reports further support the hypothesis that
pharmacokinetics can be altered during kidney disease due to
alterations in expression and activity of transporters.
Competition for renal excretion by different compounds with
similar structural characteristics has been demonstrated decades
ago in canine models [28]. These classic experiments used in vivo
models to investigate the effect of certain compounds on the renal
clearance of an entity with a similar chemical structure. However,
these models do not allow to distinguish between competitive or
non-competitive inhibition, but merely showed an overall effect on
renal clearance which includes various kinetic steps. Nowadays, by
applying molecular tools such as the membrane vesicle transport
assay, the interaction between substrates/inhibitors and a
transporter of interest can be studied in detail without the
interference of other transporters and metabolizing enzymes
present in available in vivo and in vitro models. However, the
membrane vesicle transport assay is based on the premise that in
vitro uptake is similar to in vivo efflux. Nevertheless, the use of
isolated membrane vesicles to study transport by efflux transport-
ers has been proven to be suitable in both fundamental science
and drug discovery [22]. The uremic toxins inhibit transport
predominantly in a non-competitive fashion, suggesting that the
toxins tested may use a different binding site than [3H]-MTX or
[3H]-E1S for either MRP4 or BCRP, or that the toxins are not a
substrate for the efflux pumps. It is known that MRP4 has multiple
binding sites and simultaneously transports urate and cAMP or
cGMP [10]. Moreover, there is also evidence suggesting that
BCRP contains multiple binding regions [29,30]. These findings
suggest that the toxins tested may show different inhibition profiles
when studied with other substrates for the transporters. Therefore,
it is still possible that the tested uremic toxins are also substrates for
MRP4 and BCRP. Evidently, more research is needed to fully
elucidate the molecular interaction of uremic toxins with MRP4
and BCRP.
Our study further demonstrates that uremic toxins accumulate in
patients with renal failure. We hypothesize that increasing MRP4-
and BCRP-mediated transport activity is an important therapeutic
target to prevent or reduce the accumulation of uremic toxins in
dialysis patients. This hypothesis is supported by the study of
Toyohara et al.who showed that overexpression of SLCO4C1 in the
Figure 5. Uremic toxins inhibit MRP4-mediated transport mainly in a non-competitive fashion. A rapid filtration technique was used to
study substrate specific uptake by MRP4 membrane vesicles in the presence of various concentrations of uremic toxins. Radioactivity was determined
using liquid scintillation counting. Three independent dose-response experiments were performed, each in triplicate, using different concentrations
of [3H]-MTX. A Dixon plot of the reciprocal of velocity was plotted against the concentration of different uremic toxins.
doi:10.1371/journal.pone.0018438.g005
Figure 6. Uremic toxins inhibit BCRP-mediated transport mainly in a non-competitive fashion. A rapid filtration technique was used to
study substrate specific uptake by BCRP membrane vesicles in the presence of various concentrations of uremic toxins. Radioactivity was determined
using liquid scintillation counting. Three independent dose-response experiments were performed, each in triplicate, using different concentrations
of [3H]-E1S. A Dixon plot of the reciprocal of velocity was plotted against the concentration of different uremic toxins.
doi:10.1371/journal.pone.0018438.g006
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kidney reduces plasma levels of several uremic toxins in nephrec-
tomized rats. Furthermore, they demonstrated that the transcription
of SLCO4C1 is regulated by a xenobiotic responsive core element
and that several statins induced the transcription of SLCO4C1 [7].
It would be interesting to examine whether statins, or drugs with a
similar safety and tolerability profile, affect the expression and
activity of MRP4 and BCRP.
In the present study the concentrations of five uremic toxins were
measured in patients with CRF and ESRD. The CRF patients have
severe renal insufficiency but were not yet on dialysis. The ESRD
patients were treated with either peritoneal dialysis or hemodialysis.
Plasma levels of urea and creatinine, substances not actively secreted
to a considerable extent, were quite comparable between the
groups. Still, our results indicate that the levels of several uremic
toxins were higher in the ESRD patients as compared to the CRF
patients. These results are in line with previous studies demonstrat-
ing that blood levels of indoxyl sulfate, p-cresol and uric acid are
lower in patients with residual renal function [31,32]. Thus, residual
renal function importantly contributes to the clearance of uremic
toxins, supporting the hypothesis that active transport is a necessity
for the removal of uremic toxins.
Importantly, the mean concentrations of hippuric acid, indoxyl
sulfate and phenylacetic acid reported in this study are lower than
the mean/median concentrations in patients reported in literature
Table 2. Transport inhibition occurs at clinically relevant concentrations.
MRP4
Uremic toxin IC50 (mM) IC20 (mM) Ki (mM) Cm (mM) Cu (mM) Cmax (mM)
kynurenic acid 861 1.560.3 2562 1 - 50
hippuric acid 9906180 350620 2500650 160 1380 2631
phenylacetic acid 710061600 16006170 - 18 3490a 7664b
indoxyl sulfate 17506110 530670 1000690 129 211 940
indole-3-acetic acid 179568 570630 2000670 4 5 52
BCRP
Uremic toxin IC50 (mM) IC20 (mM) Ki (mM) Cm (mM) Cu (mM) Cmax (mM)
kynurenic acid 4061 1061 50c 1 - 50
hippuric acid 36706170 690670 40006100 160 1380 2631
indoxyl sulfate 7706120 390630 500 129 211 940
Values are shown as mean (Cm; concentration determined in this study), highest mean/median (Cu) and maximal uremic concentration (Cmax). Both Cu and Cmax were
obtained from www.uremic-toxins.org, unless stated otherwise. IC50 and IC20 values are shown as mean 6 SEM of three separate experiments performed in triplicate.
aCu obtained from literature [33].
bHypothetical Cmax, calculated as Cmax = Cu + 2 SD, as previously described [19].
cKi for competitive inhibition.
doi:10.1371/journal.pone.0018438.t002
Figure 7. Accumulation of uremic toxins during CKD. HPLC was used to measure the total plasma concentrations of hippuric acid, indole-3-
acetic acid, indoxyl sulfate and phenylacetic acid. LC/MS was used to measure kynurenic acid. Plasma samples were obtained from healthy volunteers
(n = 4) and patients with CRF (n = 4) or ESRD (n = 6). Standards of the compounds were also analyzed in order to quantify the amount of toxins found
in the samples. Acquired HPLC data were processed with PC1000 software (Spectrasystem) and LC/MS data were processed with Xcaliber software
(Thermo scientific). Results are presented as mean 6 SEM. * = p,0.05 compared to control.
doi:10.1371/journal.pone.0018438.g007
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[19,33]. In contrast, the fold-increase of these toxins in ESRD
patients compared to healthy controls, are higher in our study than
in a preceding study [34]. Previously, Vanholder et al. noted that
many discrepancies exist in the reported blood levels of uremic
toxins in patients with renal failure [19]. These authors proposed
several causes for these differences, including technical reasons (e.g.
incomplete elution of compounds during chromatography or
insufficient extraction of compounds from blood) and deviations in
study population. Furthermore, it is important to notice that the
largest variations were found in the concentrations of solutes
derived from dietary intake. For example, hippuric acid is a
metabolite of phenolic compounds found in tea, wine and fruit
juices and phenylacetic acid is present in many fruits. Thus, it is
likely that differences in diet between the study populations
contribute largely to the observed variations in uremic toxin levels.
CKD is characterized by progressive and irreversible loss of
renal function and the pathophysiological mechanisms underlying
the progression of renal failure remain elusive. Concluding, several
uremic toxins inhibit substrate-specific transport by MRP4 and
BCRP at clinically relevant concentrations. Our results depict a
novel pathway via which uremic toxins impede kidney excretory
function and can contribute to accumulation of these potentially
toxic uremic retention solutes.
Supporting Information
Figure S1 Several uremic toxins do not decrease BCRP-
or MRP4-mediated transport. A rapid filtration technique
was used to study the ATP-dependent uptake of [3H]-MTX into
MRP4- overexpressing membrane vesicles (panel A) and [3H]-
E1S into BCRP membrane vesicles (panel B). in the absence or
presence of various uremic toxins (1 mM). Radioactivity was
determined using liquid scintillation counting. Results are
presented as mean 6 SEM of one representative experiment
performed in triplicate. Experiments were performed at least two
times. * = p,0.01 compared to control. IAA, indole-3-acetic
acid; Ox, oxalate; PC, p-cresol; PA, phenylacetic acid; PTA, p-
toluensulfonic acid; Pu, putrescine; QA, quinolinic acid.
(TIF)
Table S1 Results regression analysis.
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